文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

S100A8/A9阻断抑制心肌与全身炎症并减轻脓毒症诱导的心肌功能障碍

Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction.
PubMed 文献 · Crit Care · 2023-09-29
一句话结论在严重脓毒症患者中血浆S100A8/A9升高与左室收缩功能障碍及SOFA评分升高相关;小鼠内毒素血症中ABR-238901阻断S100A8/A9可预防并逆转左室功能障碍。

该研究在瑞典林雪平大学医院ICU的62例严重脓毒症患者中评估血浆S100A8/A9与心功能障碍的关系,并用小分子抑制剂ABR-238901及S100A9-/-小鼠在内毒素血症模型中做治疗与机制研究。患者中血浆S100A8/A9升高与左室收缩功能障碍及SOFA评分升高相关;野生型小鼠5 mg/kg LPS诱导血浆S100A8/A9快速升高和急性左室功能障碍。ABR-238901 30 mg/kg腹腔注射、间隔6 h给药两次,在LPS后立即给药可预防、在左室功能障碍完全建立后给药可逆转表型;地塞米松相比PBS对照未改善心功能。作者认为S100A8/A9阻断可能成为严重脓毒症患者的新治疗策略。

要点

  • 62例严重脓毒症患者中,血浆S100A8/A9升高与左室收缩功能障碍及SOFA评分升高相关。
  • 野生型小鼠5 mg/kg细菌脂多糖(LPS)诱导血浆S100A8/A9快速升高和急性左室功能障碍。
  • ABR-238901 30 mg/kg腹腔注射、间隔6 h给药两次,LPS后立即给药可预防左室功能障碍,左室功能障碍完全建立后给药可逆转表型。
  • 地塞米松相比PBS处理的內毒素血症对照未改善心脏功能。
  • S100A9-/-小鼠对LPS诱导左室功能障碍的保护程度与药物阻断S100A8/A9相当,ABR-238901在S100A9-/-小鼠中未进一步改善左室功能,证实靶点特异性。

适用人群与场景

  • 研究人群:瑞典林雪平大学医院ICU收治的62例严重脓毒症患者。
  • 动物模型:野生型小鼠及S100A9-/-小鼠的内毒素血症模型。

处置流程与药物剂量

  • 小鼠内毒素血症模型:细菌脂多糖(LPS)5 mg/kg诱导急性左室功能障碍。
  • ABR-238901 30 mg/kg腹腔注射,间隔6 h给药两次;LPS后立即给药用于预防,左室功能障碍完全建立后给药用于逆转。
  • 对照处理:地塞米松与PBS处理的內毒素血症对照比较。

研究设计与关键结果

  • 患者队列:62例严重脓毒症患者中,血浆S100A8/A9升高与左室收缩功能障碍及SOFA评分升高相关。
  • 野生型小鼠:5 mg/kg LPS诱导血浆S100A8/A9快速升高和急性左室功能障碍。
  • ABR-238901 30 mg/kg腹腔注射、间隔6 h两次,LPS后立即给药有效预防左室功能障碍,左室功能障碍完全建立后给药有效逆转表型。
  • 地塞米松相比PBS处理的內毒素血症对照未改善心脏功能。
  • S100A8/A9抑制显著降低全身炎症介质水平,阻止心肌炎症基因上调并恢复线粒体功能。
  • S100A9-/-小鼠对LPS诱导左室功能障碍的保护程度与药物性S100A8/A9阻断相当;ABR-238901在S100A9-/-小鼠中未进一步改善左室功能,证实靶点特异性。

证据类型、等级与局限

  • 证据类型:患者队列研究(62例严重脓毒症患者)联合小鼠内毒素血症模型的治疗与机制研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,S100A8/A9阻断具有强效抗炎作用、减轻心肌功能障碍,可能成为严重脓毒症患者的新治疗策略。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND AND AIMS: The triggering factors of sepsis-induced myocardial dysfunction (SIMD) are poorly understood and are not addressed by current treatments. S100A8/A9 is a pro-inflammatory alarmin abundantly secreted by activated neutrophils during infection and inflammation. We investigated the efficacy of S100A8/A9 blockade as a potential new treatment in SIMD.

METHODS: The relationship between plasma S100A8/A9 and cardiac dysfunction was assessed in a cohort of 62 patients with severe sepsis admitted to the intensive care unit of Linköping University Hospital, Sweden. We used S100A8/A9 blockade with the small-molecule inhibitor ABR-238901 and S100A9-/- mice for therapeutic and mechanistic studies on endotoxemia-induced cardiac dysfunction in mice.

RESULTS: In sepsis patients, elevated plasma S100A8/A9 was associated with left-ventricular (LV) systolic dysfunction and increased SOFA score. In wild-type mice, 5 mg/kg of bacterial lipopolysaccharide (LPS) induced rapid plasma S100A8/A9 increase and acute LV dysfunction. Two ABR-238901 doses (30 mg/kg) administered intraperitoneally with a 6 h interval, starting directly after LPS or at a later time-point when LV dysfunction is fully established, efficiently prevented and reversed the phenotype, respectively. In contrast, dexamethasone did not improve cardiac function compared to PBS-treated endotoxemic controls. S100A8/A9 inhibition potently reduced systemic levels of inflammatory mediators, prevented upregulation of inflammatory genes and restored mitochondrial function in the myocardium. The S100A9-/- mice were protected against LPS-induced LV dysfunction to an extent comparable with pharmacologic S100A8/A9 blockade. The ABR-238901 treatment did not induce an additional improvement of LV function in the S100A9-/- mice, confirming target specificity.

CONCLUSION: Elevated S100A8/A9 is associated with the development of LV dysfunction in severe sepsis patients and in a mouse model of endotoxemia. Pharmacological blockade of S100A8/A9 with ABR-238901 has potent anti-inflammatory effects, mitigates myocardial dysfunction and might represent a novel therapeutic strategy for patients with severe sepsis.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Jakobsson G, Papareddy P, Andersson H, et al. Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Crit Care. 2023. PMID: 37773186. doi:10.1186/s13054-023-04652-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。